These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 30579680)

  • 1. Letter to the Editor regarding, "The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis".
    Jayaraj R; Kumarasamy C; Samiappan S; Swaminathan P
    Oral Oncol; 2019 Mar; 90():139-140. PubMed ID: 30579680
    [No Abstract]   [Full Text] [Related]  

  • 2. Turning the tide: Clinical utility of PD-L1 expression in squamous cell carcinoma of the head and neck.
    De Meulenaere A; Vermassen T; Aspeslagh S; Huvenne W; Van Dorpe J; Ferdinande L; Rottey S
    Oral Oncol; 2017 Jul; 70():34-42. PubMed ID: 28622889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The diverse cutoff of PD-L1 positivity and negativity in studies regarding head and neck squamous cell carcinoma.
    Liu W; Chen S; Yang W
    Oral Oncol; 2018 Dec; 87():199-200. PubMed ID: 30396782
    [No Abstract]   [Full Text] [Related]  

  • 4. PD-L1 expression predicts longer disease free survival in high risk head and neck cutaneous squamous cell carcinoma.
    Roper E; Lum T; Palme CE; Ashford B; Ch'ng S; Ranson M; Boyer M; Clark J; Gupta R
    Pathology; 2017 Aug; 49(5):499-505. PubMed ID: 28666643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Bioinformatics analysis of programmed cell death ligand 1 co-expression genes and their regulatory network in head and neck squamous cell carcinoma].
    Yang LS; Shi CY; Liang YH; Liu T; Hou XR; Tian XD; Wang XY
    Hua Xi Kou Qiang Yi Xue Za Zhi; 2019 Oct; 37(5):516-520. PubMed ID: 31721500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma.
    Ock CY; Kim S; Keam B; Kim M; Kim TM; Kim JH; Jeon YK; Lee JS; Kwon SK; Hah JH; Kwon TK; Kim DW; Wu HG; Sung MW; Heo DS
    Oncotarget; 2016 Mar; 7(13):15901-14. PubMed ID: 26893364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of PD-L1 expression in pulmonary metastases from head and neck squamous cell carcinoma.
    Okada S; Itoh K; Ishihara S; Shimada J; Kato D; Tsunezuka H; Miyata N; Hirano S; Teramukai S; Inoue M
    Surg Oncol; 2018 Jun; 27(2):259-265. PubMed ID: 29937180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating tumour cell PD-L1 test for head and neck cancers.
    Kulasinghe A; Kenny L; Punyadeera C
    Oral Oncol; 2017 Dec; 75():6-7. PubMed ID: 29224824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond the Percentages of PD-L1-Positive Tumor Cells: Induced Versus Constitutive PD-L1 Expression in Primary and Metastatic Head and Neck Squamous Cell Carcinoma.
    Scognamiglio T; Chen YT
    Head Neck Pathol; 2018 Jun; 12(2):221-229. PubMed ID: 28948509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Programmed cell death-ligand 1 expression in oral squamous cell carcinoma is associated with an inflammatory phenotype.
    Satgunaseelan L; Gupta R; Madore J; Chia N; Lum T; Palme CE; Boyer M; Scolyer RA; Clark JR
    Pathology; 2016 Oct; 48(6):574-80. PubMed ID: 27590194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological role of the bidirectional interaction between epithelial-mesenchymal transition and PD-L1 expression in head and neck squamous cell carcinomas: A systematic review.
    Morais HG; Costa CS; Gonçalo RI; Carlan LM; Morais EF; Galvão HC; Freitas RD
    Med Oral Patol Oral Cir Bucal; 2023 Jul; 28(4):e395-e403. PubMed ID: 37026608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
    Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
    Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations of Tumor PD-1 Ligands, Immunohistochemical Studies, and Textural Features in
    Chen RY; Lin YC; Shen WC; Hsieh TC; Yen KY; Chen SW; Kao CH
    Sci Rep; 2018 Jan; 8(1):105. PubMed ID: 29311707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical comments on prognostic and clinicopathological significance of PD-L1 overexpression in oral squamous cell carcinoma (OSCC).
    Jayaraj R; Shetty S; Kumaraswamy C; Raghul S; Gothandam KM; Raymond G; Ravishankar RM; Shaw P
    Oral Oncol; 2020 Dec; 111():104886. PubMed ID: 32684328
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunotherapy in head and neck cancers: A new challenge for immunologists, pathologists and clinicians.
    Outh-Gauer S; Alt M; Le Tourneau C; Augustin J; Broudin C; Gasne C; Denize T; Mirghani H; Fabre E; Ménard M; Scotte F; Tartour E; Badoual C
    Cancer Treat Rev; 2018 Apr; 65():54-64. PubMed ID: 29547766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microsatellite instability associated with durable complete response to PD-L1 inhibitor in head and neck squamous cell carcinoma.
    Tardy MP; Di Mauro I; Ebran N; Refae S; Bozec A; Benezery K; Peyrade F; Guigay J; Sudaka-Bahadoran A; Badoual C; Pedeutour F; Saada-Bouzid E
    Oral Oncol; 2018 May; 80():104-107. PubMed ID: 29631799
    [No Abstract]   [Full Text] [Related]  

  • 17. The Role of the Programmed Death Receptor-1/Programmed Death Ligand-1: Immunologic Checkpoint in Human Papillomavirus-Associated Head and Neck Squamous Cell Carcinoma.
    Kunkle C; Rosado FG
    Arch Pathol Lab Med; 2018 Jun; 142(6):719-720. PubMed ID: 29848031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD274/PD-L1 gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity.
    Straub M; Drecoll E; Pfarr N; Weichert W; Langer R; Hapfelmeier A; Götz C; Wolff KD; Kolk A; Specht K
    Oncotarget; 2016 Mar; 7(11):12024-34. PubMed ID: 26918453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD44+ Cells in Head and Neck Squamous Cell Carcinoma Suppress T-Cell-Mediated Immunity by Selective Constitutive and Inducible Expression of PD-L1.
    Lee Y; Shin JH; Longmire M; Wang H; Kohrt HE; Chang HY; Sunwoo JB
    Clin Cancer Res; 2016 Jul; 22(14):3571-81. PubMed ID: 26864211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reproducibility of PD-L1 immunohistochemistry interpretation across various types of genitourinary and head/neck carcinomas, antibody clones, and tissue types.
    Wang C; Hahn E; Slodkowska E; Eskander A; Enepekides D; Higgins K; Vesprini D; Liu SK; Downes MR; Xu B
    Hum Pathol; 2018 Dec; 82():131-139. PubMed ID: 30075156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.